Last reviewed · How we verify

Omega-3 fatty acid ethyl esters

Takeda · Phase 2 active Small molecule

Activates peroxisome proliferator-activated receptor alpha (PPAR-alpha)

Activates peroxisome proliferator-activated receptor alpha (PPAR-alpha) Used for Hypertriglyceridemia.

At a glance

Generic nameOmega-3 fatty acid ethyl esters
Also known asLotriga Granular Capsules, Lotriga granular capsules
SponsorTakeda
Drug classFatty acid ethyl ester
TargetPPAR-alpha
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

Omega-3 fatty acid ethyl esters are known to reduce inflammation by activating PPAR-alpha, which regulates lipid metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: